The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin

BACKGROUND: Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial. Recent trials evidenced several cardio-renal benefits of EMPA in n...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cardiovasc Diabetol
Main Authors: Quagliariello, Vincenzo, De Laurentiis, Michelino, Rea, Domenica, Barbieri, Antonio, Monti, Maria Gaia, Carbone, Andreina, Paccone, Andrea, Altucci, Lucia, Conte, Mariarosaria, Canale, Maria Laura, Botti, Gerardo, Maurea, Nicola
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Original Investigation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8305868/
https://ncbi.nlm.nih.gov/pubmed/34301253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01346-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki